Perrigo Co. plc has released calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a treatment for psoriasis.


Perrigo, calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, Taclonex, authorized generic version, Leo Pharma, psoriasis, Joseph Papa


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Perrigo ships authorized generic of Taclonex

April 1st, 2014

DUBLIN, Ireland – Perrigo Co. plc has released calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a treatment for psoriasis.

The company said Tuesday that the product is an authorized generic version of Leo Pharma's Taclonex ointment.

Taclonex ointment is indicated for the topical treatment of plaque psoriasis of the scalp and the body in patients age 18 and older.

Sales of Taclonex totaled approximately $110 million over the last 52 weeks, according to Symphony Health Solutions data reported by Perrigo.

"This product was the result of the continued hard work and dedication of our Perrigo Rx team," stated Joseph Papa, chairman, president and chief executive officer of Perrigo. "This launch is another example of Perrigo's investment and commitment to making quality health care more affordable for consumers."

More Supplier News Breaks >>
Advertisement